Vendor Intelligence Report: HK Peptides

Published 3 Jul 2026. 26-page investigative report on who is behind HK Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 426 Finnrick lab tests, HK Peptides records 331 pass and 91 fail outcomes, for a 78% overall pass rate. HK Peptides is not a blanket buy or a blanket avoid: Tirzepatide and Retatrutide are the more defensible side of the record, while CJC-1295 and Tesamorelin sit on the wrong side of its own dispersion. The rating picture is also sensitive to stricter grading, and one Tirzepatide identity failure keeps lot-specific verification non-negotiable even on a stronger line.

The corporate trail is more complicated than the Hong Kong-facing brand suggests. The current homepage capture identifies a mainland operating company while maintaining Hong Kong geography and contact presentation; registry work did not resolve a clean Hong Kong company chain. A separate manufacturing-facing domain and mainland biotechnology record create a real industrial anchor, but the evidence stops short of signed batch records, lot-matched COAs, or a definitive retail-arm authorization.

The adjacent HKMS PEP/HomoPeptide cluster is a due-diligence issue, not a proven ownership finding. Forum material places HKMS PEP under HPT and describes shared boss/different employees, while sales handles and contact patterns overlap HK Peptides terrain. The report separates what is stated publicly from what filings do not prove.

Brand integrity is the practical risk most buyers will feel first. Lookalike HK domains, rotating social/forum channels, and a captured complaint about stolen test reports create authentication friction; PayPal-blocked and crypto-directed payment rails reduce recourse if the wrong channel or lot is used.

Inside the full report:

  • Appendix A with product-by-methodology Finnrick results, methodology-divergence charts, and trajectories for all 13 products
  • Corporate identity table comparing Hong Kong-facing claims, Henan Kuisu signals, emails, WhatsApp numbers, and registry limits
  • Manufacturing and infrastructure analysis linking hkpeptide.com, hspeptides.com, and the Henan Shengming registry record
  • HKMS PEP / HomoPeptide relationship analysis with forum statements, warehouse claims, and sales-identity overlap
  • Copycat-domain, impersonation, payment-rail, affiliate-scan, and legal/regulatory search boundaries

Risk assessment

  • Product-specific poor-performance risk — high: CJC-1295 28.38%, Tesamorelin 45.7%, TB-500 46.73%, and Sermorelin 49.02% are poor HK Peptides choices absent independent lot testing.
  • Tirzepatide identity-failure risk — high: A May 6, 2026 20 mg Tirzepatide sample reportedly contained no Tirzepatide despite Tirzepatide’s stronger 87.06% cumulative rating.
  • Corporate-transparency and rebrand risk — medium: Hong Kong branding and address do not resolve to a definitive HK Peptides registration; records point to Henan Kuisu, while related HKMS PEP uses overlapping sales identifiers and is confirmed as an HPT subsidiary.
  • Payment-recourse risk — medium: PayPal was reportedly blocked for the main brand, and buyers were pushed toward USDT, USDC, and Bitcoin, reducing refund and dispute leverage.
  • Copycat / brand-confusion risk — medium: hkpep.cc, hkpepmed.com, hk-peptide.com, and forum/social impersonation complaints create confusion, while no robust official-channel or anti-counterfeit system surfaced.